Why the study?
Do drug-eluting stents reduce in-stent restenosis compared to bare-metal stents in diabetic and non-diabetic patients?
Do drug-eluting stents reduce in-stent restenosis compared to bare-metal stents in diabetic and non-diabetic patients?
Drug-eluting stents significantly reduce in-stent restenosis compared to bare-metal stents in both diabetic and non-diabetic patients, though diabetes remains a significant risk factor for restenosis even with DES.
No takes yet. Share an insight, caveat, or question.
Endorses DES over BMS to minimize restenosis regardless of diabetes status; confirms consistent relative benefit across both populations.
Scheen et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: